SCHEMBL82681

SCHEMBL82681

O=C(O)C(F)(F)C(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4301155 0.98 THRB (0.44) THRB
SCHEMBL7941775 0.91 THRB (0.41) THRB
SCHEMBL7947965 0.81 THRB (0.33) THRB
SCHEMBL1836166 0.80 THRB (0.38) THRB
SCHEMBL18979301 0.80 THRB (0.38) THRB
SCHEMBL16418239 0.73 LMNA (0.38) THRB
SCHEMBL3056072 0.73 LMNA (0.38) THRB
SCHEMBL11402685 0.73 THRB (0.46) THRB
SCHEMBL6005211 0.72 THRB (0.46) THRB
SCHEMBL11618473 0.72 THRB (0.71) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117783362-A Method for detecting content of perfluoro and polyfluoro compound 中国计量科学研究院 2024-03-29 CN claimed
CN-117783362-A Method for detecting content of perfluoro and polyfluoro compound 中国计量科学研究院 2024-03-29 CN disclosed
US-11918645-B2 Vaccines against hepatitis B virus ALTIMMUNE UK LIMITED (GB) 2024-03-05 US disclosed
US-20240042007-A1 Fluorocarbon-Linked Peptide Formulation ALTIMMUNE UK LTD (GB) 2024-02-08 US disclosed
US-11648305-B2 Fluorocarbon-linked peptide formulation Altimmune UK Ltd. (GB) 2023-05-16 US disclosed
US-20230090379-A1 VACCINES AGAINST HEPATITIS B VIRUS ALTIMMUNE UK LIMITED (GB) 2023-03-23 US disclosed
US-11382969-B2 Vaccines against Hepatitis B virus ALTIMMUNE UK LTD (GB) 2022-07-12 US disclosed
EP-3995146-A1 VACCINES AGAINST HEPATITIS B VIRUS ALTIMMUNE UK LIMITED (GB) 2022-05-11 EP disclosed
CN-110799559-B Resin, resin composition, nonwoven fabric, fiber product, separator, secondary battery, electric double layer capacitor, and method for producing nonwoven fabric 东丽株式会社 2022-04-29 CN disclosed
US-20220073446-A1 Antigen Delivery Vectors and Constructs ALTIMMUNE UK LIMITED (GB) 2022-03-10 US disclosed
US-8110540-B2 Antigen delivery vectors and constructs IMMUNE TARGETING SYSTEMS LTD. (GB) 2012-02-07 US disclosed
EP-2374477-A1 Antigen delivery vectors and constructs Immune Targeting Systems (GB) 2011-10-12 EP disclosed
US-20100183708-A1 Antigen Delivery Vectors and Constructs IMMUNE TARGETING SYSTEMS LTD. 2010-07-22 US disclosed
US-20100183650-A1 Antigen Delivery Vectors and Constructs IMMUNE TARGETING SYSTEMS LTD. 2010-07-22 US disclosed
US-7687455-B2 comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy IMMUNE TARGETING SYSTEMS LTD. (GB) 2010-03-30 US disclosed
US-20090191233-A1 INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS IMMUNE TARGETING SYSTEMS LTD. 2009-07-30 US disclosed
EP-1740207-A2 ANTIGEN DELIVERY VECTORS AND CONSTRUCTS Immune Targeting Systems (GB) 2007-01-10 EP disclosed
US-20060013820-A1 comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy ALTIMMUNE UK LIMITED (GB) 2006-01-19 US disclosed
WO-2005099752-A9 ANTIGEN DELIVERY VECTORS AND CONSTRUCTS IMMUNE TARGETING SYSTEMS (GB) 2005-12-15 WO disclosed
WO-2005099752-A2 ANTIGEN DELIVERY VECTORS AND CONSTRUCTS IMMUNE TARGETING SYSTEMS (GB) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100183650-A1 Antigen Delivery Vectors and Constructs LY96, CD74, CD69 THRB 4280/4885
US-20230090379-A1 VACCINES AGAINST HEPATITIS B VIRUS HLA-DRB1, CD4, HLA-B THRB 457/4885
US-11918645-B2 Vaccines against hepatitis B virus HLA-DRB1, CD4, HLA-B THRB 457/4885
US-20090191233-A1 INFLUENZA ANTIGEN DELIVERY VECTORS AND CONSTRUCTS LY96, CD74, HAVCR2 THRB 3929/4885
US-20100183708-A1 Antigen Delivery Vectors and Constructs LY96, CD74, CD69 THRB 4280/4885
US-20220073446-A1 Antigen Delivery Vectors and Constructs LY96, CD74, CD69 THRB 4280/4885
US-11382969-B2 Vaccines against Hepatitis B virus CD4, HLA-DRB1, HLA-B THRB 425/4885
US-20240042007-A1 Fluorocarbon-Linked Peptide Formulation VIP, FGB, LNPEP THRB 3856/4885
US-11648305-B2 Fluorocarbon-linked peptide formulation VIP, FGB, LNPEP THRB 3856/4885
US-20060013820-A1 comprising fluorocarbon vector-antigen, immunogens; vaccines, immunotherapy LY96, CD74, HAVCR2 THRB 4469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.